An Update on Diagnosis and Classification of Axial Spondyloarthritis

Navarro-Compán, Victoria

doi:10.1007/s11926-019-0838-5

Cited by 15 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AS is a chronic, progressive, inflammatory disease that can cause loss of employment and physical deformities and requires long-term treatment. 1 The effectiveness of the treatment and a positive prognosis are directly related to patients' compliance and adherence to the treatment regimen. 5 Nurses' important responsibilities include ensuring that patients comply with medication regimens.…”

Section: Implications For Nursing Practicementioning

confidence: 99%

See 1 more Smart Citation

Assessment of the effects of loneliness, perceived social support, and depression on medication adherence in patients with ankylosing spondylitis

Öksüz¹,

Çınar

et al. 2020

Perspect Psychiatr Care

View full text Add to dashboard Cite

Purpose: This study aims to investigate the effects of loneliness, perceived social support, and depression on medication adherence of patients with ankylosing spondylitis (AS).Design and Methods: This cross-sectional study was conducted with 119 AS patients. Data were collected using the Morisky-Green-Levine Medication Adherence Scale, the UCLA Loneliness Scale (ULS), the Multidimensional Scale of Perceived Social Support (MSPSS), and the Beck Depression Inventory (BDI).Findings: Nonadherent patients were younger (P = .033), scored higher on the ULS (P = .015), and BDI (P = .024) scales, and lower on the MSPSS scale (P = .039) and on family support (P = .002).

show abstract

Section: Implications For Nursing Practicementioning

confidence: 99%

“…Symptoms of AS include, fatigue, inflammatory back pain, morning stiffness, and functional limitations. [1][2][3] A progressive disease, AS that may cause deformations and lead to unemployment since it is common among youth and adult populations. For this reason, long-term medication therapy is required to control its progression.…”

Section: Introductionmentioning

confidence: 99%

Assessment of the effects of loneliness, perceived social support, and depression on medication adherence in patients with ankylosing spondylitis

Öksüz¹,

Çınar

et al. 2020

Perspect Psychiatr Care

View full text Add to dashboard Cite

show abstract

“…Although rheumatologists play a pivotal role in caring for patients with axSpA, most patients often consult with primary care providers (e.g., primary care physicians or internalist) seeking symptom relief when they initially have their symptoms (i.e., back pain or spinal pain) and are diagnosed by primary care providers other than rheumatologists [ 5 ]. Several sets of classification criteria exist for axSpA, including the modified New York criteria [ 12 ], the Berlin criteria [ 13 ], the Amor tool [ 14 ], the European Spondylarthropathy Study Group (ESSG) criteria [ 15 ], and the Assessment of Spondyloarthritis International Society (ASAS) criteria [ 16 ]. Yet, it is not known whether healthcare providers, other than those in rheumatology, are familiar with these criteria [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study

et al. 2021

View full text Add to dashboard Cite

Background Many patients with axial spondylarthritis (axSpA) experience lengthy diagnostic delays upwards of 14 years. (5–14 years). Screening tools for axSpA have been proposed for use in primary care settings, but whether this approach could be implemented into busy primary care settings remains unknown. Objective To solicit feedback from primary care physicians regarding questions from the Inflammatory Back Pain Assessment: the Assessment of Spondyloarthritis International Society (ASAS) Expert Criteria and gain insight about barriers and facilitators for implementing axSpA screening in primary care. Methods Guided by Consolidated Criteria for reporting Qualitative Research (COREQ-criteria), we recorded, transcribed, and analyzed in-depth interviews with eight family medicine physicians and ten internists (purposeful sampling) using immersion/crystallization techniques. Results Few physicians reported awareness of existing classification criteria for axSpA, and many reported a lack of confidence in their ability to distinguish between inflammatory and mechanical back pain. From three domains, 10 subthemes emerged: 1) typical work-up of axSpA patients in primary care, with subthemes including the clues involved in work-up and role of clinical examinations for axSpA; 2) feedback on questions from the Inflammatory Back Pain Assessment: ASAS Expert Criteria, with subthemes to evaluate contents/questions of a potential screening tool for axSpA; and 3) implementation of the screening tool in primary care settings, with subthemes of perceived barriers including awareness, time, other conditions to screen, rare disease, and lack of structured questionnaire for back pain and perceived facilitators including workflow issues and awareness. Conclusions Primary care physicians believed that an improved screening instrument and a strong evidence-base to support the need for screening for axSpA are required. The implementation of axSpA screening into a busy primary care practice requires integration into the practice workflow, with use of technology suggested as a possible way to improve efficiency.

show abstract

“…Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by spinal and sacroiliac joint involvement. 1 It usually affects men at a young age, presenting with inflammatory back pain and morning stiffness. The first biological drugs with proven efficacy and safety for use with AS patients were anti-TNF-alpha antagonists.…”

Section: Introductionmentioning

confidence: 99%

Secukinumab-induced Raynaud’s phenomenon: first report in the literature

Kobak

2020

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

Secukinumab is an IL-17A antagonist that has proven efficacy in the treatment of patients with ankylosing spondylitis (AS) and psoriatic arthritis. Side effects of the drug include infections, skin rashes, and allergic reactions. Raynaud’s phenomenon (RP), a vasospastic syndrome and an important feature of different connective tissue diseases, is not an expected finding in AS patients. This article reports the development of secukinumab-related RP in a 35-year-old female patient with AS. Treatment with secukinumab was continued and RP was treated with low-dose aspirin and a calcium-channel blocker.

show abstract

An Update on Diagnosis and Classification of Axial Spondyloarthritis

Cited by 15 publications

References 37 publications

Assessment of the effects of loneliness, perceived social support, and depression on medication adherence in patients with ankylosing spondylitis

Assessment of the effects of loneliness, perceived social support, and depression on medication adherence in patients with ankylosing spondylitis

Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study

Secukinumab-induced Raynaud’s phenomenon: first report in the literature

Contact Info

Product

Resources

About